0001764013-23-000020.txt : 20230203 0001764013-23-000020.hdr.sgml : 20230203 20230203070518 ACCESSION NUMBER: 0001764013-23-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230203 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 23583712 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 8-K 1 imvt-20230203.htm 8-K imvt-20230203

Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2023
(Exact name of Registrant as specified in its Charter)

(State or other jurisdiction of incorporation or organization)
(Commission File Number)(IRS Employer Identification No.)
320 West 37th Street
New York,NY10018
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (917) 580-3099
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per shareIMVTThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.
On February 3, 2023, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal third quarter and nine months ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Current Report shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Eva Renee Barnett
 Eva Renee Barnett
 Chief Financial Officer
Date: February 3, 2023

EX-99.1 2 exhibit99120220203.htm EX-99.1 Document

Exhibit 99.1

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023

A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expected

Phase 3 clinical trial of batoclimab in myasthenia gravis (MG) is ongoing

Cash balance of approximately $433 million as of December 31, 2022

NEW YORK, February 3, 2023 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.

“We entered 2023 with renewed enthusiasm, energized by our clinical development progress and our goal to provide potentially best-in-class anti-FcRn therapies for people with autoimmune disorders,” said Pete Salzmann, M.D., chief executive officer at Immunovant. “With an expected cadence of multiple data readouts beginning mid-2023, we believe we are poised for a transformative year for the class.”

Recent Clinical Development Updates:
Immunovant plans to initiate a Phase 1 clinical trial of IMVT-1402 in early calendar year 2023, contingent on clearance of its IND application, with initial data readout from this trial expected in mid-calendar year 2023.

A Phase 3 clinical trial in TED was initiated, with topline results from the TED program (consisting of two Phase 3 clinical trials) expected in the first half of calendar year 2025.

A pivotal Phase 2b clinical trial in CIDP was initiated, with initial results from period 1 expected in the first half of calendar year 2024.

As previously disclosed, Immunovant expects to have initial results from a Phase 2 clinical trial in Graves’ disease in the second half of calendar year 2023, and expects to have top-line results from the MG clinical trial in the second half of calendar year 2024.
Based on strategic portfolio considerations, Immunovant has decided to preserve warm autoimmune hemolytic anemia (WAIHA) as a potential indication for IMVT-1402 and not pursue a WAIHA indication for batoclimab.

Financial Highlights for Fiscal Third Quarter Ended December 31, 2022:
Cash Position: As of December 31, 2022, Immunovant’s cash and cash equivalents totaled $432.6 million, which is expected to fund operations into the second half of calendar year 2025.

R&D Expenses: Research and development expenses were $42.3 million for the three months ended December 31, 2022, compared to $29.8 million for the three months ended December 31, 2021. The increase was primarily due to increased personnel-related expenses, costs related to the research and development of IMVT-1402, and higher batoclimab program-specific research and development costs (including contract manufacturing costs). These increases were partially offset by lower cross-indication clinical studies and clinical research costs.

IPR&D Expenses: Acquired in-process research and development expenses were $10.0 million for the three months ended December 31, 2022, related to the achievement of a development and regulatory milestone for batoclimab in MG as specified in the HanAll agreement. There were no acquired in-process research and development expenses for the three months ended December 31, 2021.

G&A Expenses: General and administrative expenses were $11.8 million for the three months ended December 31, 2022, compared to $11.5 million for the three months ended December 31, 2021. The increase was primarily due to higher personnel-related expenses and information technology costs, partially offset by lower financial advisory, legal and other professional fees.

Net Loss: Net loss was $63.2 million ($0.49 per common share) for the three months ended December 31, 2022, compared to $41.4 million ($0.36 per common share) for the three months ended December 31, 2021. Net loss for the three months ended December 31, 2022 and 2021 included $8.9 million and $10.2 million, respectively, related to non-cash stock-based compensation expense.

Common Stock: As of December 31, 2022, there were 129,260,254 shares of common stock issued and outstanding.

Financial Highlights for Fiscal Nine Months Ended December 31, 2022:
R&D Expenses: Research and development expenses were $108.4 million for the nine months ended December 31, 2022, compared to $69.8 million for the nine months ended December 31, 2021. The increase was primarily due to increased personnel-related expenses, costs related to the research and development of IMVT-1402, and higher batoclimab program-specific research and development costs (including contract manufacturing costs).

IPR&D Expenses: Acquired in-process research and development expenses were $10.0 million for the nine months ended December 31, 2022, related to the achievement of a development and regulatory milestone for batoclimab in MG as specified in the HanAll agreement. There were no acquired in-process research and development expenses for the nine months ended December 31, 2021.

G&A Expenses: General and administrative expenses were $35.6 million for the nine months ended December 31, 2022, compared to $39.0 million for the nine months ended December 31, 2021. The decrease was primarily due to lower financial advisory, legal, and other professional fees, partially offset by higher personnel-related expenses and information technology costs.

Net Loss: Net loss was $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022, compared to $109.6 million ($1.02 per common share) for the nine months ended December 31, 2021. Net loss for the nine months ended December 31, 2022 and 2021 included $24.8 million and $22.4 million, respectively, related to non-cash stock-based compensation expense.

About Immunovant, Inc. 
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com.

Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” "intend," and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include Immunovant’s expectations regarding the timing, design and results of clinical trials of its product candidates and indication selections; Immunovant's plan to develop batoclimab and IMVT-1402 across a broad range of autoimmune indications; Immunovant's beliefs regarding its cash runway; and the potential benefits of batoclimab’s and IMVT-1402’s unique product attributes. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; results of animal studies may not be predictive of results in humans; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the timing of the commencement of additional clinical trials and resumption of current trials; Immunovant’s scientific approach, clinical trial design, indication selection and general development progress; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of the ongoing COVID-19 pandemic, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval and commercialization of batoclimab and IMVT-1402; Immunovant is at an early stage in development of for IMVT-1402 and in various stages of clinical development for batoclimab; and Immunovant will require additional capital to fund its operations and advance batoclimab and IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s most recent Annual Report on Form 10-K, its Form 10-Q to be filed with the SEC on February 3, 2023, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)
 Three Months Ended
December 31,
Nine Months Ended
 December 31,
Operating expenses:
Research and development $42,252 $29,756 $108,420 $69,822 
Acquired in-process research and development10,000 — 10,000 — 
General and administrative
11,775 11,515 35,597 38,984 
Total operating expenses64,027 41,271 154,017 108,806 
Interest income, net(2,944)— (4,098)— 
Other expense1,757 114 609 825 
Loss before provision (benefit) for income taxes(62,840)(41,385)(150,528)(109,631)
Provision (benefit) for income taxes387 — 1,000 (72)
Net loss$(63,227)$(41,385)$(151,528)$(109,559)
Net loss per common share – basic and diluted
Weighted-average common shares outstanding – basic and diluted
128,574,190 115,025,191 120,665,299 107,447,745 

Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share data)
December 31,March 31,
Current assets:
Cash and cash equivalents$432,608 $493,817 
Accounts receivable704 12,229
Prepaid expenses and other current assets21,110 6,885
Total current assets454,422 512,931
Operating lease right-of-use assets1,459 2,303
Property and equipment, net362 330
Total assets$456,243 $515,564 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$14,004 $18,629 
Accrued expenses26,050 24,746
Current portion of operating lease liabilities1,205 1,145
Total current liabilities41,259 44,520
Operating lease liabilities, net of current portion306 1,219
Total liabilities41,565 45,739
Commitments and contingencies
Stockholders’ equity:
Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at December 31, 2022 and March 31, 2022
— — 
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and March 31, 2022
— — 
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 129,260,254 shares issued and outstanding at December 31, 2022 and 500,000,000 shares authorized, 116,482,899 shares issued and outstanding at March 31, 2022
13 12
Additional paid-in capital920,197 824,796
Accumulated other comprehensive income1,383 404
Accumulated deficit(506,915)(355,387)
Total stockholders’ equity414,678 469,825
Total liabilities and stockholders’ equity$456,243 $515,564 

Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.

EX-101.SCH 3 imvt-20230203.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 imvt-20230203_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 imvt-20230203_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Feb. 03, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 03, 2023
Entity Registrant Name IMMUNOVANT, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38906
Entity Tax Identification Number 83-2771572
Entity Address, Address Line One 320 West 37th Street
Entity Address, City or Town New York,
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10018
City Area Code 917
Local Phone Number 580-3099
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol IMVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001764013
Amendment Flag false
XML 7 imvt-20230203_htm.xml IDEA: XBRL DOCUMENT 0001764013 2023-02-03 2023-02-03 0001764013 false 8-K 2023-02-03 IMMUNOVANT, INC. DE 001-38906 83-2771572 320 West 37th Street New York, NY 10018 917 580-3099 false false false false Common Stock, $0.0001 par value per share IMVT NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://immunovant.com/role/Cover Cover Cover 1 false false All Reports Book All Reports imvt-20230203.htm exhibit99120220203.htm imvt-20230203.xsd imvt-20230203_lab.xml imvt-20230203_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imvt-20230203.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "imvt-20230203.htm" ] }, "labelLink": { "local": [ "imvt-20230203_lab.xml" ] }, "presentationLink": { "local": [ "imvt-20230203_pre.xml" ] }, "schema": { "local": [ "imvt-20230203.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "imvt", "nsuri": "http://immunovant.com/20230203", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imvt-20230203.htm", "contextRef": "ifd869995a3a3445abc61b4f2d949710a_D20230203-20230203", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://immunovant.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "imvt-20230203.htm", "contextRef": "ifd869995a3a3445abc61b4f2d949710a_D20230203-20230203", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunovant.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001764013-23-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001764013-23-000020-xbrl.zip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end